Koshika Soma

Pfizer (United States) — United States

Medicine · Health Sciences

17h-index3.1kcitations29works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(19), Autoimmune and Inflammatory Disorders Research(11), Systemic Lupus Erythematosus Research(8), Chronic Lymphocytic Leukemia Research(8), Herpesvirus Infections and Treatments(4)

Publications29 total

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Dermatology and Therapy·2025Open Access
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development
Drug Discovery Today·2024· 3 cited
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Arthritis Research & Therapy·2021· 10 citedOpen Access
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States
Contemporary Clinical Trials·2021· 50 citedOpen Access
Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral Strategy
Research Square (Research Square)·2021Open Access
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
Annals of the Rheumatic Diseases·2020· 19 citedOpen Access
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
Clinical Rheumatology·2020· 21 citedOpen Access
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
RMD Open·2019· 51 citedOpen Access
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
Arthritis Care & Research·2019· 37 citedOpen Access
THU0193 EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (≤2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY
Annals of the Rheumatic Diseases·2019· 4 citedOpen Access
Risk Factors for Major Adverse Cardiovascular Events in Phase <scp>III</scp> and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Arthritis & Rheumatology·2019· 72 citedOpen Access
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Arthritis Research & Therapy·2019· 313 citedOpen Access
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
Rheumatology and Therapy·2018· 14 citedOpen Access
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
JCR Journal of Clinical Rheumatology·2018· 15 citedOpen Access
The Effectiveness of Zoster Vaccine in Patients Subsequently Treated With Tofacitinib
The American Journal of Gastroenterology·2017
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
Arthritis & Rheumatology·2017· 122 citedOpen Access
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
The Lancet·2017· 480 cited
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
Seminars in Arthritis and Rheumatism·2016· 132 citedOpen Access
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
Annals of the Rheumatic Diseases·2016· 98 citedOpen Access
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Annals of the Rheumatic Diseases·2015· 77 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Roy Fleischmann(7), Lisy Wang(7), Kenneth Kwok(6), Christina Charles‐Schoeman(5), Ryan DeMasi(5), Noriko Iikuni(5), J. Wollenhaupt(4), Birgitta Benda(4), David Gruben(4), Richard J. Riese(4), Kevin Winthrop(4), Pinaki Biswas(4), David Scholfield(4), Gerd R Burmester(3), Cristiano A. F. Zerbini(3), Sriram Krishnaswami(3), Eduardo Mysler(3), Stephen Hall(3), Robert J. Moots(3), Liza Takiya(3)